Suppr超能文献

健康个体中凝血酶生成试验(有和无血栓调节蛋白)的生物学变异数据和分析规范目标估计。

Biological variation data and analytical specification goal estimates of the thrombin generation assay with and without thrombomodulin in healthy individuals.

机构信息

Département des Laboratoires Cliniques, Cliniques Universitaires Saint-Luc, Brussels, Belgium.

出版信息

Int J Lab Hematol. 2021 Jun;43(3):450-457. doi: 10.1111/ijlh.13388. Epub 2020 Nov 13.

Abstract

BACKGROUND

Evaluation of an individual's thrombin-generating capacity enables a global assessment of the coagulation cascade and is therefore thought to better reflect the clotting function of blood. However, the lack of standardization still hampers the use in routine clinical practice.

METHODS

Nineteen healthy subjects were sampled once a week for 5 consecutive weeks. Thrombin generation assay (TGA) was performed in duplicate by calibrated automated thrombogram (CAT) on platelet poor plasma with and without thrombomodulin. After exclusion of outliers, a nested analysis of variance (ANOVA) was performed to evaluate the biological variability (BV) results. Analytical variation (CV ), within-individual variation (CV ), between-individual variation (CV ), index of individuality (II), and reference change value (RCV) were calculated.

RESULTS

All parameters taken together, the CV CV , and CV without TM, ranged from 2.8% to 6.5%, from 4.1% to 13.3% and from 10.4% to 28.4%, respectively. For TG with TM, CV and CV were higher and ranged from 5.0% to 18.1% and from 14.9% to 35.3%, respectively. For endogenous thrombin potential (ETP), a CV of 4.1% and CV of 10.4% were obtained without addition of thrombomodulin (TM). With addition of TM, both CV and CV were higher: 14.0% and 34.8%, respectively. The II was low and the RCV ranged from 17.2% to 50.4%.

CONCLUSION

CAT parameters are highly individualized and population-based reference values could be called into question. The assessment of BV and RCV for thrombin generation assays could optimize interpretation of serial patient results and guide setting of analytical specification goals.

摘要

背景

评估个体的凝血酶生成能力可以全面评估凝血级联反应,因此被认为能更好地反映血液的凝血功能。然而,缺乏标准化仍然阻碍了其在常规临床实践中的应用。

方法

19 名健康受试者连续 5 周每周采集一次样本。采用校准的自动血栓图(CAT)在血小板缺乏的血浆中重复进行两次凝血酶生成试验(TGA),并分别加入和不加入血栓调节蛋白(TM)。剔除离群值后,采用嵌套方差分析(ANOVA)评估生物学变异(BV)结果。计算分析变异(CV)、个体内变异(CV)、个体间变异(CV)、个体指数(II)和参考变化值(RCV)。

结果

所有参数综合来看,无 TM 时的 CV CV 和 CV 分别为 2.8%6.5%、4.1%13.3%和 10.4%28.4%。有 TM 时的 CV 和 CV 较高,分别为 5.0%18.1%和 14.9%35.3%。对于内源性凝血酶潜能(ETP),不添加血栓调节蛋白(TM)时,CV 为 4.1%,CV 为 10.4%。添加 TM 后,CV 和 CV 均升高:分别为 14.0%和 34.8%。II 较低,RCV 范围为 17.2%50.4%。

结论

CAT 参数具有高度个体性,基于人群的参考值可能值得质疑。评估凝血酶生成试验的 BV 和 RCV 可以优化对连续患者结果的解释,并指导分析规范目标的设定。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验